Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	The OLB Group	Pacific West Bank	SilverSun Technologies	Logiq	Protagenic Therapeutics
Symbol	NASDAQ:OLB	OTCMKTS:PWBO	NASDAQ:SSNT	OTCMKTS:WEYL	OTCMKTS:PTIX
Price Information
Current Price	$5.46	$16.00	$9.00	$3.25	$2.16
50-Day Moving Average	$5.57	$15.65	$9.37	$2.97	$2.61
52-Week Low	$3.26	$9.56	$2.20	$1.62	$1.05
52-Week High	$16.40	$18.00	$14.87	$10.50	$7.00
MarketRank™
Overall Score	1.9	0.0	1.5	1.0	1.2
Analysis Score	3.5	0.0	0.0	0.0	0.0
Community Score	5.0	0.0	4.0	5.0	4.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	3.3	0.0	1.7
Earnings & Valuation Score	0.0	0.0	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	N/A	N/A	N/A	N/A
Consensus Price Target	$9.00	N/A	N/A	N/A	N/A
% Upside from Price Target	64.84% upside	N/A	N/A	N/A	N/A
Trade Information
Market Cap	$38.85 million	$42.45 million	$45.55 million	$43.27 million	$31.63 million
Beta	N/A	0.13	1.09	1.43	-0.52
Average Volume	358,590	653	92,992	23,703	338,917
Sales & Book Value
Annual Revenue	$9.77 million	N/A	$41.22 million	$34.65 million	N/A
Price / Sales	3.97	N/A	1.10	1.25	N/A
Cashflow	N/A	N/A	$0.29 per share	N/A	N/A
Price / Cash	N/A	N/A	31.22	N/A	N/A
Book Value	$0.93 per share	N/A	$1.62 per share	$1.22 per share	($0.11) per share
Price / Book	5.87	N/A	5.56	2.66	N/A
Profitability
Net Income	$-1,780,000.00	N/A	$180,000.00	$-6,540,000.00	$-2,550,000.00
EPS	N/A	N/A	N/A	N/A	N/A
Trailing P/E Ratio	N/A	0.00	0.00	N/A	N/A
Forward P/E Ratio	∞	∞	∞	∞	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-24.90%	N/A	1.96%	-21.55%	N/A
Return on Equity (ROE)	-26.48%	N/A	9.06%	-59.07%	N/A
Return on Assets (ROA)	-17.20%	N/A	4.72%	-50.00%	-398.88%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.02%	N/A	0.05%	0.02%	N/A
Current Ratio	6.32%	N/A	1.93%	3.38%	0.30%
Quick Ratio	6.32%	N/A	1.93%	3.38%	0.30%
Ownership Information
Institutional Ownership Percentage	1.92%	15.85%	9.53%	N/A	N/A
Insider Ownership Percentage	N/A	N/A	44.94%	9.50%	45.00%
Miscellaneous
Employees	24	N/A	165	17	N/A
Shares Outstanding	7.11 million	2.65 million	5.06 million	13.31 million	14.64 million
Next Earnings Date	8/16/2021 (Estimated)	N/A	8/11/2021 (Estimated)	N/A	N/A
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Protagenic Therapeutics (OTCMKTS:PTIX) Stock Passes Above Two Hundred Day Moving Average of $0.00 americanbankingnews.com - July 27 at 2:44 AM
	Protagenic Therapeutics Updates on Patient Enrollment for PT00114 Trial, Shares Lower marketwatch.com - July 23 at 7:33 PM
	Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 ... apnews.com - July 23 at 7:33 PM
	Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial finance.yahoo.com - July 23 at 7:33 PM
	Digital Media Solutions (NYSE:DMS) versus Protagenic Therapeutics (OTCMKTS:PTIX) Critical Comparison americanbankingnews.com - July 19 at 1:22 AM
	Head to Head Contrast: Quhuo (NASDAQ:QH) versus Protagenic Therapeutics (OTCMKTS:PTIX) americanbankingnews.com - July 13 at 6:12 PM
	Protagenic Therapeutics (OTCMKTS:PTIX) Shares Cross Above 200 Day Moving Average of $0.00 americanbankingnews.com - July 10 at 1:30 AM
	Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10 00 AM ET wallstreet-online.de - July 6 at 11:20 PM
	Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET finance.yahoo.com - July 6 at 8:05 AM
	Selling Your CoProtagenic Therapeutics Inc. (NASDAQ: PTIX) mpany Stock? Here’s What You Need To Know stocksregister.com - July 1 at 8:56 AM
	Protagenic Therapeutics Inc. (NASDAQ:PTIX) – Analysts See The Stock Differently Today marketingsentinel.com - June 30 at 7:13 AM
	What Could Change After Protagenic Therapeutics Inc. (NASDAQ: PTIX) Gains 66.24% From The High-Point? marketingsentinel.com - June 25 at 9:39 AM
	The Next Few Weeks Are A Good Time To Consider Protagenic Therapeutics Inc. (PTIX) stocksregister.com - June 24 at 8:26 AM
	Is Protagenic Therapeutics Inc. (NASDAQ: PTIX) Dead In The Water? stocksregister.com - June 21 at 9:09 AM
	Top Moving Stock Now – Protagenic Therapeutics Inc. (NASDAQ: PTIX) stocksregister.com - June 16 at 10:04 AM
	Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th finance.yahoo.com - June 16 at 10:04 AM
	Protagenic Therapeutics Inc. Shares Are Down -82.66% Since The Beginning Of The Year marketingsentinel.com - June 15 at 8:33 AM
	Protagenic Therapeutics Inc. [PTIX] is 182.86% higher this YTD. Is it still time to buy? dbtnews.com - June 14 at 7:01 PM
	Protagenic Therapeutics Inc. barrons.com - June 13 at 2:06 PM
	Protagenic Therapeutics Inc. (NASDAQ: PTIX) Stock Seems Like A Good Option stocksregister.com - June 11 at 3:45 PM
	What Should You Do With Protagenic Therapeutics Inc. (NASDAQ: PTIX) At Current Prices? marketingsentinel.com - June 11 at 10:45 AM
	Protagenic Therapeutics Inc. [PTIX] is 156.19% higher this YTD. Is it still time to buy? dbtnews.com - May 27 at 5:43 AM
	How is the Protagenic Therapeutics, Inc. (NASDAQ:PTIX) performance outlook for the coming months? marketingsentinel.com - May 26 at 10:17 AM
	What Will Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Be Like After It Drops -126.39% From Its Highs? marketingsentinel.com - May 22 at 10:56 AM
	Protagenic Therapeutics Inc. [PTIX] is 108.57% higher this YTD. Is it still time to buy? dbtnews.com - May 17 at 10:07 PM

Date	Company	Brokerage	Action
1/6/2021	The OLB Group	Aegis	Boost Price Target
10/1/2020	The OLB Group	Aegis	Initiated Coverage
12/19/2018	SilverSun Technologies	Dawson James	Reiterated Rating
8/24/2018	SilverSun Technologies	Westpark Capital	Set Price Target

(Data available from 8/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources